- Trials with a EudraCT protocol (32)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
32 result(s) found for: Homeostatic Model Assessment.
Displaying page 1 of 2.
EudraCT Number: 2012-000870-51 | Sponsor Protocol Number: CMCS240281 | Start Date*: 2013-02-25 |
Sponsor Name:Unidad de Gestión Clínica de Endocrinología y Nutrición | ||
Full Title: RANDOMIZED CLINICAL TRIAL TO ASSESS THE EFFICACY OF TESTOSTERONE UNDECANOATE, METFORMIN, OR THE COMBINATION OF BOTH, FOR THE TREATMENT OF ISOLATED HYPOGONADOTROPIC HYPOGONADISM AND ERECTILE DYSFUNC... | ||
Medical condition: Isolated hypogonadotropic hypogonadism related to obesity | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2016-004124-26 | Sponsor Protocol Number: CBYM338X2211 | Start Date*: 2017-09-16 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: A randomized, subject- and investigator-blinded, placebo-controlled study to assess the safety, pharmacokinetics and efficacy of intravenous bimagrumab in overweight and obese patients with type 2 ... | |||||||||||||
Medical condition: Diabetes Mellitus, Type 2 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003400-12 | Sponsor Protocol Number: GFT505E-218-1 | Start Date*: 2019-10-17 | |||||||||||
Sponsor Name:GENFIT | |||||||||||||
Full Title: An Open Label, Randomized, Multicenter Study to Assess the Pharmacokinetic and Pharmacodynamic Profile and the Safety and Tolerability of Two Dose Levels of Elafibranor (80 mg and 120 mg) in Childr... | |||||||||||||
Medical condition: Non-Alcoholic Steato-Hepatitis (NASH) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-001452-30 | Sponsor Protocol Number: 010815testis | Start Date*: 2015-12-07 | |||||||||||
Sponsor Name:Copenhagen University Hospital Rigshospitalet | |||||||||||||
Full Title: A Randomized double-blind study of testosterone replacement therapy or placebo in testicular cancer survivors with mild Leydig Cell Insufficiency (Einstein-intervention) | |||||||||||||
Medical condition: Leydig Cell dysfunction | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-006114-14 | Sponsor Protocol Number: 62326B1658 | Start Date*: 2012-04-17 |
Sponsor Name:Research and Development department | ||
Full Title: “Effects of testosterone on glycaemic control and other Cardiovascular Risk factors in Hypogonadal Men with uncontrolled Type 2 Diabetes: A randomized double – blinded placebo controlled add on tr... | ||
Medical condition: Hypogonadism Type 2 Diabetes Cardiovascular risk | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2013-000121-31 | Sponsor Protocol Number: PSYK-TREAT-HEALTHY | Start Date*: 2013-03-20 | |||||||||||
Sponsor Name:Prof., dr. med. Anders Fink-Jensen | |||||||||||||
Full Title: Does a GLP-1 receptor agonist change glucose tolerance in antipsychotic-treated patients? | |||||||||||||
Medical condition: Dysglycaemia, schizophrenia, paranoid psycosis, schizotypal disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-006967-22 | Sponsor Protocol Number: R076477-SCH-3020 | Start Date*: 2007-10-08 | |||||||||||
Sponsor Name:Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium | |||||||||||||
Full Title: A Prospective Randomized Open-label 6-Month Head-To-Head Trial to Compare Metabolic Effects of Paliperidone ER and Olanzapine in Subjects with Schizophrenia | |||||||||||||
Medical condition: Subjects 18 – 65 years of age, who meets the DSM-IV criteria for schizophrenia with a PANSS total score at screening of 60-100 inclusive. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Completed) SE (Prematurely Ended) GR (Completed) EE (Completed) FR (Completed) GB (Prematurely Ended) IT (Completed) SK (Completed) LV (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004370-96 | Sponsor Protocol Number: LG-TCS-AD | Start Date*: 2019-02-15 | |||||||||||
Sponsor Name:Jacob Pontoppidan Thyssen | |||||||||||||
Full Title: The effects of topical corticosteroid use on insulin sensitivity and bone turnover | |||||||||||||
Medical condition: Atopic dermatitis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000231-27 | Sponsor Protocol Number: NN8640-4263 | Start Date*: 2019-04-23 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: A trial comparing the effect and safety of once weekly dosing of somapacitan with daily Norditropin® in children with growth hormone deficiency | |||||||||||||
Medical condition: Growth hormone deficiency in children | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) FR (Ongoing) DK (Completed) AT (Ongoing) SI (Ongoing) GB (GB - no longer in EU/EEA) NO (Ongoing) IE (Completed) EE (Completed) LV (Ongoing) PL (Ongoing) HU (Ongoing) ES (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000232-10 | Sponsor Protocol Number: NN8640-4245 | Start Date*: 2019-05-15 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: A dose-finding trial evaluating the effect and safety of once-weekly treatment of somapacitan compared to daily Norditropin® in children with short stature born small for gestational age with no ca... | |||||||||||||
Medical condition: Short stature in children born small for gestational age with no catch-up growth by 2 years of age or older | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) FR (Ongoing) GB (GB - no longer in EU/EEA) AT (Ongoing) NO (Ongoing) IE (Completed) EE (Completed) HU (Trial now transitioned) LV (Ongoing) PL (Completed) ES (Prematurely Ended) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-001140-61 | Sponsor Protocol Number: GWDM1302 | Start Date*: 2013-12-30 | |||||||||||
Sponsor Name:GW Research Ltd. | |||||||||||||
Full Title: A randomised, double blind, placebo controlled, parallel group, dose ranging study of GWP42004 as add on to metformin in the treatment of participants with Type 2 diabetes. | |||||||||||||
Medical condition: Type 2 diabetes | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-004765-40 | Sponsor Protocol Number: SPR001-204 | Start Date*: 2020-11-17 | |||||||||||
Sponsor Name:Spruce Biosciences, Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SPR001 (Tildacerfont) in Reducing Supraphysiologic Glucocorticoid Use in Adult Subjects with Classic Co... | |||||||||||||
Medical condition: Classic Congenital Adrenal Hyperplasia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Trial now transitioned) NL (Trial now transitioned) DE (Ongoing) SE (Trial now transitioned) PL (Trial now transitioned) LT (Trial now transitioned) IT (Ongoing) EE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000099-27 | Sponsor Protocol Number: HEAT01 | Start Date*: 2017-04-26 | |||||||||||
Sponsor Name:The Department of Urology | |||||||||||||
Full Title: Toxicity of first-line abiraterone versus enzalutamide in men with metastatic castration-resistant prostate cancer: A randomized clinical trial | |||||||||||||
Medical condition: Metastisc castration resistant prostate cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-006025-73 | Sponsor Protocol Number: 01-06-TL-322OPI-004 | Start Date*: 2007-04-18 | |||||||||||
Sponsor Name:Takeda Global Research & Development Centre (Europe) Limited, | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind Study to Determine the Efficacy and Safety of the Addition of SYR-322 25 mg versus Dose Titration from 30 mg to 45 mg of ACTOS® Pioglitazone HCl in Subjects ... | |||||||||||||
Medical condition: Type II Diabetes Mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) GB (Completed) FR (Completed) BE (Completed) DE (Completed) NL (Prematurely Ended) AT (Completed) ES (Completed) GR (Prematurely Ended) DK (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-001371-37 | Sponsor Protocol Number: GDM-TREAT | Start Date*: 2012-07-10 | ||||||||||||||||
Sponsor Name:Dr. med. Tina Vilsbøll | ||||||||||||||||||
Full Title: The impact of liraglutide on glucose tolerance and the risk of type 2 diabetes in women with previous gestational diabetes mellitus | ||||||||||||||||||
Medical condition: Gestational diabetes mellitus Non-alcoholic fatty liver disease | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Female | |||||||||||||||||
Trial protocol: DK (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-004647-20 | Sponsor Protocol Number: COR-2017-OLE | Start Date*: 2018-11-13 | |||||||||||
Sponsor Name:Cortendo AB | |||||||||||||
Full Title: An Open-label Extension Study of Levoketoconazole (2S,4R-ketoconazole) in the Treatment of Endogenous Cushing’s Syndrome | |||||||||||||
Medical condition: Endogenous Cushing´s syndrome (CS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) BG (Completed) ES (Ongoing) IT (Ongoing) NL (Completed) GR (Completed) RO (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-003575-11 | Sponsor Protocol Number: VitaminD&TT | Start Date*: 2013-03-05 | |||||||||||
Sponsor Name:Medizinische Universität Graz, Innere Medizin | |||||||||||||
Full Title: A randomized, double-blind, placebo controlled trial to evaluate the effects of vitamin D supplementation on androgen levels in hypogonadal men | |||||||||||||
Medical condition: Male hypogonadism (total testosterone <3ng/ml) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: AT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-004506-34 | Sponsor Protocol Number: 16.022 | Start Date*: 2017-01-26 | |||||||||||
Sponsor Name:Odense Universitetshospital | |||||||||||||
Full Title: The effect of myoinositol (MI) or metformin treatment on symptoms of polycystisk ovary syndrome (PCOS), including metabolism, menstrual pattern, quality of life and mental health. | |||||||||||||
Medical condition: Polycystic ovarian syndrome (PCOS) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000102-28 | Sponsor Protocol Number: AFJ2020-1 | Start Date*: 2020-08-19 | |||||||||||
Sponsor Name:Mental Healt Center Copenhagen | |||||||||||||
Full Title: Does the glucagon-like peptide-1 receptor agonist semaglutide prevent deterioration in glycaemic control in prediabetic or diabetic patients with schizophrenia spectrum disorder treated with the an... | |||||||||||||
Medical condition: Schizophrenia spectrum disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-003320-40 | Sponsor Protocol Number: EP-003 | Start Date*: 2023-03-14 | |||||||||||
Sponsor Name:Empros Pharma AB | |||||||||||||
Full Title: A 26-week, double-blind, randomized study in participants with overweight or obesity investigating the added contribution of acarbose in EMP16 on efficacy, safety and tolerability | |||||||||||||
Medical condition: Obesity | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.